Letters Avastin versus Lucentis

The scientific community should lobby to be able to apply for drug licences

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e3553 (Published 22 May 2012) Cite this as: BMJ 2012;344:e3553
  1. Silvio Garattini, director1,
  2. Vittorio Bertele’, head, drug regulatory policies laboratory1
  1. 1Mario Negri Institute for Pharmacological Research, via Giuseppe La Masa 19, 20156 Milan, Italy
  1. silvio.garattini{at}marionegri.it

Torjesen and Campbell and colleagues recently stoked the Avastin-Lucentis embers.1 2 3 4 This is a classic case of industry not only having no interest in applying for a new indication but also having a specific interest in not doing so. It is disappointing that public …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial